{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:31:46Z","timestamp":1784403106655,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The percentage of cells staining positive for Ki67 is sometimes used for decision-making in patients with early invasive breast cancer (IBC). However, there is uncertainty regarding the most appropriate Ki67 cut points and the influence of interlaboratory measurement variability. We examined the relationship between breast cancer mortality and Ki67 both before and after accounting for interlaboratory variability and 8 patient and tumor characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicenter cohort study of women with early IBC diagnosed during 2009-2016 in more than 20 NHS hospitals in England and followed until December 31, 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ki67 was strongly prognostic of breast cancer mortality in 8212 women with estrogen receptor (ER)\u2013positive, human epidermal growth factor receptor 2 (HER2)\u2013negative early IBC (Ptrend\u2009&amp;lt;\u2009.001). This relationship remained strong after adjustment for patient and tumor characteristics (Ptrend\u2009&amp;lt;\u2009.001). Standardization for interlaboratory variability did little to alter these results. For women with Ki67 scores of 0%-5%, 6%-10%, 11%-19%, and 20%-29% the corresponding 8-year adjusted cumulative breast cancer mortality risks were 3.3% (95% confidence interval [CI] = 2.8% to 4.0%), 3.7% (95% CI = 3.0% to 4.4%), 3.4% (95% CI = 2.8% to 4.1%), and 3.4% (95% CI = 2.8% to 4.1%), whereas for women with Ki67 scores of 30%-39% and 40%-100%, these risks were higher, at 5.1% (95% CI = 4.3% to 6.2%) and 7.7% (95% CI = 6.6% to 9.1) (Ptrend\u2009&amp;lt;\u2009.001). Similar results were obtained when the adjusted analysis was repeated with omission of pathological information about tumor size and nodal involvement, which would not be available preoperatively for patients being considered for neoadjuvant therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings confirm the prognostic value of Ki67 scores of 30% or more in women with ER-positive, HER2-negative early IBC, irrespective of interlaboratory variability. These results also suggest that Ki67 may be useful to aid decision-making in the neoadjuvant setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkad054","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:44:11Z","timestamp":1691801051000},"source":"Crossref","is-referenced-by-count":14,"title":["Ki67 and breast cancer mortality in women with invasive breast cancer"],"prefix":"10.1093","volume":"7","author":[{"given":"Jake","family":"Probert","sequence":"first","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Broggio","sequence":"additional","affiliation":[{"name":"The National Disease Registration Service, NHS England , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Charman","sequence":"additional","affiliation":[{"name":"The National Disease Registration Service, NHS England , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kerr","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McGale","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Taylor","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C","family":"Darby","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-9474","authenticated-orcid":false,"given":"Gurdeep S","family":"Mannu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford , Oxford, UK"},{"name":"Nuffield Department of Surgical Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"22","key":"2023091410221399800_pkad054-B1","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2023091410221399800_pkad054-B2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2023091410221399800_pkad054-B3","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12\u2009155 patients","volume":"96","author":"de Azambuja","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"2023091410221399800_pkad054-B4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023091410221399800_pkad054-B5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1186\/1471-2407-14-908","article-title":"Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer","volume":"14","author":"Wishart","year":"2014","journal-title":"BMC Cancer"},{"issue":"12","key":"2023091410221399800_pkad054-B6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"2023091410221399800_pkad054-B7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1200\/JCO.21.02742","article-title":"FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer","volume":"40","author":"Royce","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023091410221399800_pkad054-B8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","article-title":"Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients","volume":"17","author":"Stuart-Harris","year":"2008","journal-title":"Breast"},{"key":"2023091410221399800_pkad054-B9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2017.07.041","article-title":"Interlaboratory variability of Ki67 staining in breast cancer","volume":"84","author":"Focke","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023091410221399800_pkad054-B10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pathol.2016.11.006","article-title":"Ki67 assessment in breast cancer: an update","volume":"49","author":"Penault-Llorca","year":"2017","journal-title":"Pathology"},{"key":"2023091410221399800_pkad054-B11","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/npjbcancer.2016.14","article-title":"Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration","volume":"2","author":"Leung","year":"2016","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2023091410221399800_pkad054-B12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41379-018-0109-4","article-title":"An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer","volume":"32","author":"Rimm","year":"2019","journal-title":"Mod Pathol"},{"key":"2023091410221399800_pkad054-B13","first-page":"393","article-title":"Clinical use of the oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer","volume":"9","author":"McVeigh","year":"2017","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"2","key":"2023091410221399800_pkad054-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","article-title":"Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone","volume":"176","author":"Sestak","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2023091410221399800_pkad054-B15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41379-020-0643-8","article-title":"Prosigna\u00ae breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK\u2122) index for breast cancer prognosis","volume":"34","author":"Baskota","year":"2021","journal-title":"Modern Pathol"},{"key":"2023091410221399800_pkad054-B16","first-page":"506","article-title":"MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients","author":"Cardoso"},{"issue":"10","key":"2023091410221399800_pkad054-B17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","article-title":"Clinical utility of gene-expression signatures in early stage breast cancer","volume":"14","author":"Kwa","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2023091410221399800_pkad054-B18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"32","key":"2023091410221399800_pkad054-B19","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1200\/JCO.2010.31.2835","article-title":"Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer","volume":"29","author":"Cuzick","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023091410221399800_pkad054-B20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","article-title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium","volume":"181","author":"Dietz","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2023091410221399800_pkad054-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-020-0168-9","article-title":"Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic","volume":"6","author":"Dowsett","year":"2020","journal-title":"NPJ Breast Cancer"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkad054\/51100424\/pkad054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/5\/pkad054\/51550764\/pkad054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/5\/pkad054\/51550764\/pkad054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:52:29Z","timestamp":1694706749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkad054\/7241520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkad054","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,8,11]]},"article-number":"pkad054"}}